Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel
Standard
Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel : results from a multi-center phase II study of the NOGGO. / Oskay-Oezcelik, Guelten; Koensgen, Dominique; Hindenburg, Hans-Joachim; Klare, Peter; Schmalfeldt, Barbara; Lichtenegger, Werner; Chekerov, Radoslav; Al-Batran, Salah-Eddin; Neumann, Ulf; Sehouli, Jalid; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO).
in: ANTICANCER RES, Jahrgang 28, Nr. 2B, 29.05.2008, S. 1329-34.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel
T2 - results from a multi-center phase II study of the NOGGO
AU - Oskay-Oezcelik, Guelten
AU - Koensgen, Dominique
AU - Hindenburg, Hans-Joachim
AU - Klare, Peter
AU - Schmalfeldt, Barbara
AU - Lichtenegger, Werner
AU - Chekerov, Radoslav
AU - Al-Batran, Salah-Eddin
AU - Neumann, Ulf
AU - Sehouli, Jalid
AU - Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO)
PY - 2008/5/29
Y1 - 2008/5/29
N2 - BACKGROUND: Pegylated liposomal doxorubicin (PLD) is one of the most effective cytotoxic agents in recurrent ovarian cancer. Palmar-plantar erythrodysesthesia (PPE) is a typical and commonly noted adverse event and often represents the dose-limiting toxicity. The purpose of this multicenter study was to determine the efficacy of this regimen as second-line therapy for patients with recurrent ovarian cancer.PATIENTS AND METHODS: Patients with recurrent epithelial ovarian cancer after surgery and initial treatment with carboplatin and paclitaxel were enrolled. Eligible patients were required to have an ECOG performance status of < or =2, and sufficient organ function. PLD was administered at a dose of 20 mg/m2 every two weeks.RESULTS: Twenty patients were recruited into this trial. Overall, 155 cycles of chemotherapy with a median of six courses (range 4-24) were administered. The median patient age was 64 years (range, 41-77 years). The hematological and non-hematological toxicity profile was favorable. No grade IV toxicity was observed. PPE grade III toxicity was noted in only one patient. Median overall survival was 19.2 months (range 1.8 to 39 months; 95% confidence interval (CI) 14.2-29.7 months) Progression-free survival was 3.3 months (range 1.38 to 36.4 months; 95% CI 1.84-13.4 months).CONCLUSION: Biweekly PLD is an effective second-line treatment for patients with relapsed ovarian cancer. Toxicity incidence with this treatment schedule does not appear to be associated with the number of previous chemotherapies. Our data supports the need for a randomized study comparing biweekly with conventional monthly administration of 40 mg/m2 or 50 mg/m2 PLD to determine the best therapeutic index for PLD.
AB - BACKGROUND: Pegylated liposomal doxorubicin (PLD) is one of the most effective cytotoxic agents in recurrent ovarian cancer. Palmar-plantar erythrodysesthesia (PPE) is a typical and commonly noted adverse event and often represents the dose-limiting toxicity. The purpose of this multicenter study was to determine the efficacy of this regimen as second-line therapy for patients with recurrent ovarian cancer.PATIENTS AND METHODS: Patients with recurrent epithelial ovarian cancer after surgery and initial treatment with carboplatin and paclitaxel were enrolled. Eligible patients were required to have an ECOG performance status of < or =2, and sufficient organ function. PLD was administered at a dose of 20 mg/m2 every two weeks.RESULTS: Twenty patients were recruited into this trial. Overall, 155 cycles of chemotherapy with a median of six courses (range 4-24) were administered. The median patient age was 64 years (range, 41-77 years). The hematological and non-hematological toxicity profile was favorable. No grade IV toxicity was observed. PPE grade III toxicity was noted in only one patient. Median overall survival was 19.2 months (range 1.8 to 39 months; 95% confidence interval (CI) 14.2-29.7 months) Progression-free survival was 3.3 months (range 1.38 to 36.4 months; 95% CI 1.84-13.4 months).CONCLUSION: Biweekly PLD is an effective second-line treatment for patients with relapsed ovarian cancer. Toxicity incidence with this treatment schedule does not appear to be associated with the number of previous chemotherapies. Our data supports the need for a randomized study comparing biweekly with conventional monthly administration of 40 mg/m2 or 50 mg/m2 PLD to determine the best therapeutic index for PLD.
KW - Adult
KW - Aged
KW - Antibiotics, Antineoplastic
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Doxorubicin
KW - Drug Administration Schedule
KW - Female
KW - Humans
KW - Middle Aged
KW - Organoplatinum Compounds
KW - Ovarian Neoplasms
KW - Paclitaxel
KW - Polyethylene Glycols
M3 - SCORING: Journal article
C2 - 18505074
VL - 28
SP - 1329
EP - 1334
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 2B
ER -